475 related articles for article (PubMed ID: 19151801)
1. [Risk factors for hepatitis C among injecting drug users in Oslo].
Dalgard O; Egeland A; Ervik R; Vilimas K; Skaug K; Steen TW
Tidsskr Nor Laegeforen; 2009 Jan; 129(2):101-4. PubMed ID: 19151801
[TBL] [Abstract][Full Text] [Related]
2. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
3. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
Kemp R; Miller J; Lungley S; Baker M
N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
[TBL] [Abstract][Full Text] [Related]
4. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users.
Robinson GM; Reynolds JN; Robinson BJ
N Z Med J; 1995 Mar; 108(996):103-5. PubMed ID: 7715873
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern.
Habib SE; Lovejoy FH; Aspin C
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):823-34. PubMed ID: 12041560
[TBL] [Abstract][Full Text] [Related]
7. Irish injecting drug users and hepatitis C: the importance of the social context of injecting.
Smyth BP; Barry J; Keenan E
Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users.
Mathei C; Shkedy Z; Denis B; Kabali C; Aerts M; Molenberghs G; Van Damme P; Buntinx F
J Viral Hepat; 2006 Aug; 13(8):560-70. PubMed ID: 16901287
[TBL] [Abstract][Full Text] [Related]
9. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.
Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS
Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
[TBL] [Abstract][Full Text] [Related]
11. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
[TBL] [Abstract][Full Text] [Related]
12. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users.
Vidal-Trecan GM; Varescon-Pousson I; Gagnière B; Tcherny- Lessenot S; Madariaga E; Boissonnas A
Ann Med Interne (Paris); 2002 Jun; 153(4):219-25. PubMed ID: 12218887
[TBL] [Abstract][Full Text] [Related]
13. Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County, Sweden.
Norden L; Saxon L; Kåberg M; Käll K; Franck J; Lidman C
Scand J Infect Dis; 2009; 41(10):727-34. PubMed ID: 19688640
[TBL] [Abstract][Full Text] [Related]
14. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users.
Burt RD; Thiede H; Hagan H
Drug Alcohol Depend; 2009 Dec; 105(3):215-20. PubMed ID: 19720473
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
16. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
[TBL] [Abstract][Full Text] [Related]
17. Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs.
Ward J; Topp L; Iversen J; Wand H; Akre S; Kaldor J; Maher L
Aust N Z J Public Health; 2011 Oct; 35(5):421-6. PubMed ID: 21973248
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of hepatitis C infection in injecting drug users in Zadar County, Croatia.
Medić A; Dzelalija B; Sonicki Z; Zekanović D
Coll Antropol; 2008 Sep; 32(3):697-702. PubMed ID: 18982740
[TBL] [Abstract][Full Text] [Related]
19. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.
Palmateer N; Hutchinson S; McAllister G; Munro A; Cameron S; Goldberg D; Taylor A
J Viral Hepat; 2014 Jan; 21(1):25-32. PubMed ID: 24329854
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
